Clinical Trial Update: Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating the efficacy and safety of BCD-033 and Rebif for multiple sclerosis has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BCD-033 (interferon beta-1a biosimilar)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Biocad | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-02-17